TIEGHI, Alessia
 Distribuzione geografica
Continente #
NA - Nord America 468
EU - Europa 152
AS - Asia 108
Totale 728
Nazione #
US - Stati Uniti d'America 460
DE - Germania 57
CN - Cina 47
SG - Singapore 39
IT - Italia 23
TR - Turchia 20
UA - Ucraina 18
RU - Federazione Russa 13
FR - Francia 10
GB - Regno Unito 10
CA - Canada 8
FI - Finlandia 8
SE - Svezia 5
BE - Belgio 3
NL - Olanda 3
ID - Indonesia 2
IE - Irlanda 1
LT - Lituania 1
Totale 728
Città #
Fairfield 70
Woodbridge 66
Santa Clara 40
Cambridge 32
Chandler 31
Singapore 31
Houston 30
Ashburn 28
Seattle 28
Wilmington 20
Jacksonville 16
Beijing 11
San Diego 10
Shanghai 9
Ann Arbor 8
New York 8
Izmir 6
Los Angeles 6
Nanjing 6
Addison 5
Fidenza 5
Milan 5
Princeton 5
Boardman 4
Dearborn 4
Toronto 4
Bremen 3
Brussels 3
Falkenstein 3
London 3
Orange 3
Ottawa 3
Bologna 2
Ferrara 2
Helsinki 2
Jakarta 2
Jiaxing 2
Jinan 2
Munich 2
Nanchang 2
Rome 2
Auburn Hills 1
Changsha 1
Clearwater 1
Cormeilles-en-Parisis 1
Dublin 1
Frankfurt am Main 1
Indiana 1
Istanbul 1
Kilburn 1
Lappeenranta 1
Ningbo 1
Shenyang 1
Shenzhen 1
Taizhou 1
Tianjin 1
Vancouver 1
Verona 1
Zhengzhou 1
Totale 542
Nome #
P2X7 receptor expression in evolutive and indolent forms of chronic B lymphocytic leukemia 150
Soluble urokinase-type Plasminogen Activator Receptor (suPAR) as an independent factor predicting worse prognosis and extra bone marrow involvement in multiple myeloma patients 137
Clinical importance of interphase cytogenetics detecting occult chromosome lesions in myelodysplastic syndromes with normal karyotype 132
Chronic lymphocytic leukemia with 6q- shows distinct hematological features and intermediate prognosis 126
Dendritic cells in acute promyelocytic leukaemia 121
Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis 25
Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: A Real-World PV-NET Study 21
A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis 18
Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib 16
Totale 746
Categoria #
all - tutte 3.833
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.833


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202061 0 0 0 0 0 0 15 15 10 12 8 1
2020/202163 5 3 19 6 0 7 1 7 0 8 5 2
2021/202275 8 6 6 0 9 3 2 1 1 7 7 25
2022/202372 5 2 5 10 13 9 5 6 13 0 3 1
2023/202444 3 4 0 1 4 9 4 2 2 1 5 9
2024/2025139 6 16 20 16 34 37 10 0 0 0 0 0
Totale 746